A-kinase anchoring protein 12Genealiases: AKAP250 · SSeCKS
Q-omics provides the consensus-scored AKAP12 profile across patient tissues and cancer cell-line models. AKAP12 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AKAP12 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, AKAP12 protein abundance shows 27,569 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where AKAP12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKAP12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKAP12 survival associations across molecular data types. AKAP12 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKAP12 RNA expression–survival associations across cancer types. High AKAP12 expression shows unfavorable associations in LUAD, ACC, LUSC, OV and STAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AKAP12 RNA expression.
This table summarizes AKAP12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for AKAP12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKAP12 shows lower tumor expression in COAD, THCA, KICH, BLCA, UCEC and LUSC. The COAD box plot shows higher AKAP12 RNA expression in normal versus tumor tissue (log2 FC = −1.714, t-test p < 0.001).
This table shows molecular features associated with AKAP12 in patient tissues and cancer cell lines. In patient samples, AKAP12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, AKAP12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
